To the Editor: Sweeney et al. (Aug. 20 issue)(1) report a marked survival advantage with concomitant docetaxel and androgen-deprivation therapy (ADT), as compared with ADT alone, in patients with hormone-sensitive metastatic prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
However, it would be interesting to compare the experimental group with the subgroup of the control group that received subsequent docetaxel after the development of castration resistance to clarify the effect of timing on patient outcomes. In addition, the survival benefit was more pronounced in high-risk patients, with an extraordinary hazard ratio of 0. 61. This underlines the need for more accurate models integrating data on disease volume . . .
The New England journal of medicine. 2016 Jan 21 [Epub]
Chiara Ciccarese, Matteo Santoni, Francesco Massari